INTECH Investment Management’s Taysha Gene Therapies TSHA Stock Holding History

INTECH Investment Management’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$358K	Buy	52,618 +4,630	+10%	+$27.4K	﹤0.01%	1488
2026 Q1	$215K	Sell	47,988 -23,081	-32%	-$107K	﹤0.01%	1724
2025 Q4	$391K	Buy	71,069 +2,443	+4%	+$11.9K	﹤0.01%	1625
2025 Q3	$224K	Sell	68,626 -13,569	-17%	-$38.4K	﹤0.01%	1995
2025 Q2	$190K	Sell	82,195 -17,717	-18%	-$38.5K	﹤0.01%	2109
2025 Q1	$139K	Buy	99,912 +31,877	+47%	+$53.3K	﹤0.01%	2219
2024 Q4	$118K	Buy	68,035 +25,941	+62%	+$53.8K	﹤0.01%	2179
2024 Q3	$84.6K	Buy	+42,094	New	+$92.4K	﹤0.01%	1916

Other funds holding TSHA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

INTECH Investment Management's TSHA Position: Q2 2026 in Review

INTECH Investment Management increased its Taysha Gene Therapies (TSHA) stake by 9.6% in Q2 2026, buying an estimated $27.4K and bringing the position to 52,618 shares worth $358K. The position accounts for ﹤0.01% of the portfolio, ranked #1488.

INTECH Investment Management first reported a position in TSHA in Q3 2024 and has held it in 8 quarters since. The position peaked at $391K in Q4 2025. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

INTECH Investment Management held 52,618 shares of Taysha Gene Therapies worth $358K as of Q2 2026.
INTECH Investment Management bought 4,630 Taysha Gene Therapies shares in Q2 2026, an estimated $27.4K.
Taysha Gene Therapies made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1488 holding.
INTECH Investment Management first reported a position in Taysha Gene Therapies in Q3 2024 and has held it in 8 quarters since.
INTECH Investment Management's Taysha Gene Therapies position peaked at $391K in Q4 2025.
208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.